WoundReference improves clinical decisions
 Choose the role that best describes you
Bekheit M, Baddour N, Katri K, Taher Y, El Tobgy K, Mousa E, et al.
BMJ open gastroenterology. Date of publication 2016 Apr 28;volume 3(1):e000082.
1. BMJ Open Gastroenterol. 2016 Apr 28;3(1):e000082. doi: 10.1136/bmjgast-2016-000082. eCollection 2016. Hyperbaric oxygen therapy stimulates colonic stem cells and induces mucosal healing in patients with refractory ulcerative colitis: a prospective case series. Bekheit M(1), Baddour N(2), Katri K(3), Taher Y(4), El Tobgy K(5), Mousa E(3). Author information: (1)Department of Surgery, El Kabbary General Hospital, Alexandria, Egypt; Department of Surgery, Faculty of Medicine, Alexandria Main University Hospital, Alexandria, Egypt. (2)Department of Pathology, Faculty of Medicine , Alexandria Main University Hospital , Alexandria , Egypt. (3)Department of Surgery, Faculty of Medicine , Alexandria Main University Hospital , Alexandria , Egypt. (4)Department of Internal Medicine, Faculty of Medicine , Alexandria Main University Hospital , Alexandria , Egypt. (5)Department of Hyperbaric Medicine , Naval Hospital , Alexandria , Egypt. BACKGROUND: Hyperbaric oxygen (HBO) is used as part of treatment in a variety of clinical conditions. Its use in the treatment of ulcerative colitis has been reported in few clinical reports. OBJECTIVE: We report the effect of HBO on refractory ulcerative colitis exploring one potential mechanism of action. DESIGN: A review of records of patients with refractory ulcerative colitis who received HBO was conducted. Clinical and histopathological scoring was utilised to evaluate the response to HBO therapy (HBOT). RESULTS: All patients manifested clinical improvement by the 40th cycle of HBOT. The median number of stool frequency dropped from seven motions/day (range=3-20) to 1/day (range=0.5-3), which was significant (z=-4.6, p<0.001). None of the patients manifested persistent blood passage after HBOT (z=-3.2, p=0.002). The severity index significantly improved after HBOT (z=-4.97, p<0.001). Histologically, a significant reduction of the scores of activity was recorded accompanied by a significant increase in the proliferating cell nuclear antigen labelling index of the CD44 cells of the colonic mucosa (p=0.001). CONCLUSIONS: HBOT is effective in the setting of refractory ulcerative colitis. The described protocol is necessary for successful treatment. HBOT stimulates colonic stem cells to promote healing. DOI: 10.1136/bmjgast-2016-000082 PMCID: PMC4860723 PMID: 27195128
Appears in following Topics:
Investigational HBOT Indications - Inflammatory Bowel Disease